Robotic-assisted surgery as an enabling technology for ovarian-sparing management in pediatric benign ovarian tumours: a comparative study - Takeaways - MDSpire

Robotic-assisted surgery as an enabling technology for ovarian-sparing management in pediatric benign ovarian tumours: a comparative study

  • By

  • M. M. Cantagalli

  • Marco Di Mitri

  • Antonino Morabito

  • A. Brucculeri

  • S. Muscolino

  • E. Severi

  • E. Bencini

  • F. Fierro

  • Enrico Ciardini

  • Riccardo Coletta

  • June 18, 2026

  • 0 min

Share

  • 1

    Robotic-assisted surgery achieved a 100% ovarian-sparing rate in pediatric patients, compared to 85.7% in the pre-robotic cohort.

  • 2

    No conversions to open surgery occurred in the robotic cohort, while two conversions happened in the pre-robotic group.

  • 3

    Operative time was longer in the robotic cohort, with a median of 2:27:30 compared to 1:42:00 in the pre-robotic cohort.

  • 4

    Postoperative opioid rescue therapy was significantly less frequent in the robotic cohort at 10% versus 50% in the pre-robotic cohort.

  • 5

    Robotic-assisted surgery demonstrated no intraoperative complications or surgical site infections in the pediatric cohort.

Original Source(s)

Robotic-assisted surgery as an enabling technology for ovarian-sparing management in pediatric benign ovarian tumours: a comparative study

  • by M. M. Cantagalli, Marco Di Mitri, Antonino Morabito, A. Brucculeri, S. Muscolino, E. Severi, E. Bencini, F. Fierro, Enrico Ciardini, Riccardo Coletta

  • June 18, 2026

Related Content

Global research trends and hotspots in human immunodeficiency virus-associated cervical cancer (1990–2025): a multi-database bibliometric analysis

Comprehensive Cancer Care for the Doral Community

Baptist Health Cancer Care is now serving patients in Doral with a comprehensive, community-based approach to oncology care designed to make treatment more convenient and accessible for both patients and referring physicians.

  • by

  • June 2, 2026

  • 2 min
Assessing Eligibility for Anticancer Drug Health Insurance Reimbursement Using Large Language Models: Benchmark Development and Comparative Study